The Potential of SERMs for Reducing the Risk of Coronary Heart Disease
- 1 October 1999
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 10 (8) , 320-325
- https://doi.org/10.1016/s1043-2760(99)00182-4
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Comment on Lack of Effect of Raloxifene on Coronary Artery Atherosclerosis of Postmenopausal MonkeysJournal of Clinical Endocrinology & Metabolism, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Tamoxifen Inhibits Arterial Accumulation of LDL Degradation Products and Progression of Coronary Artery Atherosclerosis in MonkeysArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Effect of tamoxifen on measurements of hemostasis in healthy womenArchives of internal medicine (1960), 1996
- Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)Atherosclerosis, 1996
- Endothelial dysfunction in coronary heart diseaseCurrent Opinion in Cardiology, 1996
- A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal womenJournal of Bone and Mineral Research, 1996
- The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal womenJournal of Clinical Endocrinology & Metabolism, 1995
- Book ReviewAmbulatory Pediatric CareNew England Journal of Medicine, 1989